Good morning. Elizabeth Cooney sitting in for Ed Silverman on what from here looks like a perfect summer day. Before you leave your laptop for the weekend, here are some news items to ponder. As Ed would say, fire up some stimulation and keep us in mind should you have spicy tips to share.
Even when all responses are “never” to six questions on a website co-sponsored by Biogen (BIIB), maker of the controversial new Alzheimer’s drug Aduhelm — such as, do you lose your train of thought or feel a bit more anxious — the quiz still issues a “talk to your doctor” recommendation about the potential need for additional cognitive testing, Kaiser Health News says. The campaign — which also includes a detailed advertisement on The New York Times’ website, a Facebook page, and partnerships aimed at increasing the number of places where consumers can get cognitive testing — is drawing fire from critics.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
